Abstract
Alzheimers disease (AD) is accompanied by an activation of the innate immune system, and many epidemiological studies have shown reduced risk for dementia or AD associated with chronic consumption of non-steroidal anti-inflammatory drugs (NSAIDS). These observations led to animal model studies to test the hypothesis that NSAIDs can be disease-modifying for some aspects of AD pathogenesis. NSAIDS cannot only suppress inflammatory targets, which could contribute to neuroprotection, they also slow amyloid deposition by mechanisms that remain unclear. Several large clinical trials with NSAID therapies with AD subjects have failed, and cyclooxygenase-2 does not appear to be a useful target for disease modifying therapy. However, there may be apolipoprotein E E4 pharmacogenomic effects and a real but delayed positive signal in a large primary prevention trial with naproxen. This encourages researchers to re-address possible mechanisms for a stage-dependent NSAID efficacy, the subject of this review.
Keywords: Alzheimer's disease, cyclooxygenases, non-steroidal anti-inflammatory drugs, docosahexaenoic acid, curcumin
CNS & Neurological Disorders - Drug Targets
Title: Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs for the Prevention of Alzheimers Disease
Volume: 9 Issue: 2
Author(s): Greg M. Cole and Sally A. Frautschy
Affiliation:
Keywords: Alzheimer's disease, cyclooxygenases, non-steroidal anti-inflammatory drugs, docosahexaenoic acid, curcumin
Abstract: Alzheimers disease (AD) is accompanied by an activation of the innate immune system, and many epidemiological studies have shown reduced risk for dementia or AD associated with chronic consumption of non-steroidal anti-inflammatory drugs (NSAIDS). These observations led to animal model studies to test the hypothesis that NSAIDs can be disease-modifying for some aspects of AD pathogenesis. NSAIDS cannot only suppress inflammatory targets, which could contribute to neuroprotection, they also slow amyloid deposition by mechanisms that remain unclear. Several large clinical trials with NSAID therapies with AD subjects have failed, and cyclooxygenase-2 does not appear to be a useful target for disease modifying therapy. However, there may be apolipoprotein E E4 pharmacogenomic effects and a real but delayed positive signal in a large primary prevention trial with naproxen. This encourages researchers to re-address possible mechanisms for a stage-dependent NSAID efficacy, the subject of this review.
Export Options
About this article
Cite this article as:
Cole Greg M. and Frautschy Sally A., Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs for the Prevention of Alzheimers Disease, CNS & Neurological Disorders - Drug Targets 2010; 9 (2) . https://dx.doi.org/10.2174/187152710791011991
DOI https://dx.doi.org/10.2174/187152710791011991 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuroactive Steroids as Endogenous Modulators of Anxiety
Current Pharmaceutical Design Ginkgo biloba Extract 761: A Review of Basic Studies and Potential Clinical Use in Psychiatric Disorders
CNS & Neurological Disorders - Drug Targets In Vitro Blood-Brain Barrier Models – Latest Advances and Therapeutic Applications in a Chronological Perspective
Mini-Reviews in Medicinal Chemistry Preclinical and Clinical Studies on Bryostatins, A Class of Marine-Derived Protein Kinase C Modulators: A Mini-Review
Current Topics in Medicinal Chemistry Neuroprotective Effects of Ellagitannins: A Brief Review
Current Drug Targets Gene Therapy: How to Target the Kidney. Promises and Pitfalls
Current Gene Therapy Acute Transient Psychoses and their Differentiation from Schizophrenia
Current Psychiatry Reviews The Potential Therapeutic Role of the HMGB1-TLR Pathway in Epilepsy
Current Drug Targets Perspectives on Medicinal Properties of Benzoquinone Compounds
Mini-Reviews in Medicinal Chemistry Acethylcholinesterase Inhibition, Antibacterial and Antioxidant Properties of Diaryl Oxalates
Current Enzyme Inhibition Toll-Like Receptors and Inflammation in the CNS
Current Drug Targets - Inflammation & Allergy Tau in Alzheimer Disease and Related Tauopathies
Current Alzheimer Research miRNAs in Alzheimer Disease – A Therapeutic Perspective
Current Alzheimer Research The Differential Diagnostic Value of the Callosal Angle and Evans Index in Mild Cognitive Impairment and Alzheimer's Disease
Current Medical Imaging Thrombolysis in Ischemic Stroke: Focus on New Treatment Strategies
Recent Patents on Cardiovascular Drug Discovery Increased Alzheimer’s Disease Neuropathology is Associated with Type 2 Diabetes and ApoE ε4 Carrier Status
Current Alzheimer Research A Longitudinal FDG-PET Study of Transgenic Mice Overexpressing GSK- 3β in the Brain
Current Alzheimer Research Estrogen and Cytokines Production - The Possible Cause of Gender Differences in Neurological Diseases
Current Pharmaceutical Design Neuron-to-microglia Crosstalk in Psychiatric Disorders
Current Neuropharmacology Meet the Editorial Board Member
Current Neuropharmacology